<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924972</url>
  </required_header>
  <id_info>
    <org_study_id>OPHTH-011018</org_study_id>
    <nct_id>NCT04924972</nct_id>
  </id_info>
  <brief_title>FACE-Q in Blepharoplasty</brief_title>
  <official_title>Face-Q Patient-Report Assisted Subjective and Objective Evaluation of Upper Eye Lid Blepharoplasty Outcomes Using Different Suturing Techniques: A Randomized Observer and Patient-Blinded Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of two different suturing techniques in&#xD;
      patients undergoing bilateral upper eyelid blepharoplasty on the results of the FACE-Q Eye&#xD;
      Module questionnaire for measuring patient-reported outcomes as well as on the blinded&#xD;
      objective assessment by two experienced surgeons using the same questionnaire.&#xD;
&#xD;
      We aim to investigate the differences of the 2 most common techniques of skin closure with&#xD;
      running cutaneous or subcuticular Nylon (6-0 Prolene) sutures in upper blepharoplasties and&#xD;
      their effect on postoperative complications and scar formation. Besides the functional&#xD;
      outcomes (visual field) and objective postoperative results, we aim to measure the patients'&#xD;
      satisfaction using the FACE-Q Eye Module as a comprehensive, procedure- and disease-specific&#xD;
      patient-reported outcome instrument.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall patient satisfaction</measure>
    <time_frame>3 months</time_frame>
    <description>Questionaire: FACE-Q eye module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FACE-Q eye module: individual questions</measure>
    <time_frame>3 months</time_frame>
    <description>Questionaire: FACE-Q eye module</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dermatochalasis of Upper Eyelid</condition>
  <arm_group>
    <arm_group_label>Intracutaneous Suture</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>running Suture</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blepharoplasty</intervention_name>
    <description>90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.</description>
    <arm_group_label>Intracutaneous Suture</arm_group_label>
    <arm_group_label>running Suture</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ninety patients will be enrolled in the study. Eligibility will be assessed at the first&#xD;
        visit based on inclusion/exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Women and men between 18-99 years&#xD;
&#xD;
          -  With bilateral dermatochalasis and resulting visual field restriction&#xD;
&#xD;
          -  Willingness and ability to comply with regular visits&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Any disease affecting wound closure/healing such as diabetes, connective tissue&#xD;
             disease or non-medically induced bleeding disorders, known autoimmune disease, known&#xD;
             tendency for hypertrophic scars or keloids;&#xD;
&#xD;
          -  Untreated hypertension or metabolic syndrome,&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Asymmetric brow ptosis,&#xD;
&#xD;
          -  Previous surgery on the eye lids&#xD;
&#xD;
          -  Sequelae after facial nerve palsy&#xD;
&#xD;
          -  Allergy or adverse reaction to any substance or material used.&#xD;
&#xD;
          -  Active or chronic eyelid inflammation&#xD;
&#xD;
        Pregnant or breast-feeding women:&#xD;
&#xD;
        Women of childbearing potential (18-50) are not excluded form this study. Breastfeeding or&#xD;
        pregnant women are however excluded, as bilateral upper eye lid blepharoplasty can be&#xD;
        easily postponed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Reinhard Told</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

